Skip to Content

Rule

Change of Address; Biologics License Applications; Technical Amendment

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 19585

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending its regulations to update the address for applicants to submit biologics license applications (BLAs) and BLA amendments and supplements regulated by the Center for Drug Evaluation and Research (CDER). This action is being taken to ensure accuracy and clarity in the Agency's regulations.

DATES:

This rule is effective April 2, 2013.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Scott E. Zeiss, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 1120, Silver Spring, MD 20993-0002, 301-796-0639.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is amending 21 CFR 600.2(b) to update the address for applicants to submit BLAs and BLA amendments and supplements regulated by CDER. The new address for all these submissions is CDER Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901B Ammendale Rd., Beltsville, MD 20705. This action is being taken to ensure accuracy and clarity in the Agency's regulations.

Publication of this document constitutes final action on these changes under the Administrative Procedure Act (5 U.S.C. 553). FDA has determined that notice and public comment are unnecessary because this amendment to the regulations provides only technical changes to update an address for the submission of BLAs and BLA amendments and supplements.

Start List of Subjects

List of Subjects for 21 CFR Part 600

  • Biologics
  • Reporting and recordkeeping requirements
End List of Subjects

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 600 is amended as follows:

Start Part

PART 600—BIOLOGICAL PRODUCTS: GENERAL

End Part Start Amendment Part

1. The authority citation for 21 CFR part 600 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 360i, 371, 374; 42 U.S.C. 216, 262, 263, 263a, 264, 300aa-25.

End Authority
[Amended]
Start Amendment Part

2. Section 600.2 is amended in the first sentence of paragraph (b) by removing “CDER Therapeutic Biological Products Document Room” and adding in its place “CDER Central Document Room”, and by removing “12229 Wilkins Ave., Rockville, MD 20852” and adding in its place “5901B Ammendale Rd., Beltsville, MD 20705”.

End Amendment Part Start Signature

Dated: March 27, 2013.

Peter Lurie,

Acting Associate Commissioner for Policy and Planning.

End Signature End Supplemental Information

[FR Doc. 2013-07578 Filed 4-1-13; 8:45 am]

BILLING CODE 4160-01-P